Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | MicrobiomeTrials← Back to trialsNCT05389423
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-06-27Est. Completion: 2028-06-01
Enrollment target: 25 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
DLBCL - Diffuse Large B Cell Lymphoma
This study will ultimately aim at providing the scientific community with patient-reported health status data that will …
Bologna, ItalyCompleted Feb 15, 2024
Mantle Cell Lymphoma (MCL)Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Waldenström Macroglobulinemia (WM)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and c…
Multiple Locations
Est. completion Jun 30, 2029
Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedEpstein-Barr Virus (EBV) Infection
This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 i…
Lexington, United StatesEst. completion Oct 1, 2028